Neurosoft Bioelectronics Closes $7.5M Oversubscribed Seed Round for Stretchable Brain-Computer Interfaces
Summary
Neurosoft Bioelectronics, a Switzerland-headquartered neurotechnology company with a US presence in New York, closed a $7.5 million oversubscribed seed round led by Skybound Venture Capital with participation from PL Capital, IAG Capital Partners, and Connecticut Innovations. The company has now raised more than $20 million total. Neurosoft develops soft, stretchable brain interfaces that sit on the cortical surface without penetrating tissue, and is building a neural data foundation model trained on large-scale human neural recordings.
Why it matters
Neurosoft's round underscores investor interest in BCIs that avoid penetrating brain tissue, while its foundation model strategy positions the company at the intersection of neuroscience and AI. The partnership with Science Corporation to provide BCI ecosystem access reduces the cost of building a full platform from $75-100 million to under $5 million.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial